Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Larry Bornstein

Psychiatry Everett, WA Medical Doctor

NPI 1548343577 CMS profile 25223

811 Madison St, Everett, WA 98203

Open in the dashboard

General payments

$662,741

802 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Larry Bornstein of Everett, WA is reported in the CMS Open Payments database as having received $662,741 across 802 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,435 27
2024 General $125,807 144
2023 General $141,873 140
2022 General $41,364 39
2021 General $11,477 9
2020 General $73,164 89
2019 General $241,622 354

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Bornstein
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Larry Bornstein were reported at $27,435. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Larry Bornstein Psychiatry median Middle half National median
2019 $241,622 $184 $59–$605 $163
2020 $73,164 $119 $36–$372 $114
2021 $11,477 $143 $43–$576 $132
2022 $41,364 $153 $50–$590 $149
2023 $141,873 $170 $56–$651 $160
2024 $125,807 $179 $57–$673 $164
2025 $27,435 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $526,549 554 payments
  2. Neurocrine Biosciences, Inc. $113,776 200 payments
  3. Otsuka America Pharmaceutical, Inc. $16,392 33 payments
  4. Sunovion Pharmaceuticals Inc. $3,818 8 payments
  5. Janssen Pharmaceuticals, Inc $2,059 5 payments
  6. Alkermes, Inc. $120 1 payment
  7. E.R. Squibb & Sons, L.L.C. $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $561,941 200 payments
  2. Travel and Lodging $80,634 368 payments
  3. Food and Beverage $14,465 231 payments
  4. Consulting Fee $5,701 3 payments
Products named General payments · program years 2019–2025
  1. AUSTEDO $270,377 277 payments
  2. UZEDY $179,365 187 payments
  3. INGREZZA Neurology $109,026 196 payments
  4. Austedo XR $75,547 82 payments
  5. ABILIFY MAINTENA $16,392 33 payments
  6. LATUDA $3,798 7 payments
  7. INGREZZA Neurology $2,750 3 payments
  8. INVEGA SUSTENNA $2,059 5 payments
  9. INGREZZA Neuropsychiatry $2,000 1 payment
  10. INVEGA TRINZA $1,360 3 payments
  11. Other $1,507 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

404

Median for Psychiatry: 574

Drug cost

$39,409

Median for Psychiatry: $27,624

Branded share of claims

13.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 16 $23,725
Divalproex Sodium Generic 27 $4,172
Clozapine Generic 28 $3,788
Oxcarbazepine Generic 13 $1,448
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 22 $1,332
Lurasidone Hcl Generic 14 $631
Quetiapine Fumarate Generic 30 $627
Olanzapine Generic 11 $483
Sertraline Hcl Generic 24 $438
Trazodone Hcl Generic 28 $426

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
  • Teva Pharmaceuticals USA, Inc. $78,452
$78,452 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $47,328
$47,328 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

802 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record